Stay updated with breaking news from Refractory Multiple. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Media contact: Investor contact: ...
In case you missed it, below is a recap of all drugs that have been approved by the FDA in February 2024.
Currently, the safety and efficacy of linvoseltamab in adult patients with relapsed or refractory multiple myeloma is being compared to elotuzumab, pomalidomide, and dexamethasone in a phase 3 clinical trial.
/PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...
Experts discuss treatment in newly diagnosed multiple myeloma and the role of CAR T-cell therapies and bispecifics in relapsed/refractory disease.